A new generation of targeted therapeutics for the treatment of cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA195926-01
Agency Tracking Number: R41CA195926
Amount: $299,275.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA16-414
Timeline
Solicitation Year: 2016
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-06-01
Award End Date (Contract End Date): 2017-05-31
Small Business Information
351 W 10TH ST STE 510, Indianapolis, IN, 46202-4100
DUNS: 963580894
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 KATHERINE PAWELCZAK
 (937) 554-4954
 kspawelczak@nerxbiosciences.com
Business Contact
 JOHN TURCHI
Phone: (317) 612-4672
Email: jturchi@nerxbiosciences.com
Research Institution
 INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
 980 Indiana Avenue
Lockfield Village, RM 2232
INDIANAPOLIS, IN, 46202-2915
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast majorities of lung cancers are diagnosed in older individuals and can be attributed to complications from tobacco smoke exposure where it has been estimated that one mutation is generated for every cigarettes smoked While we have made significant strides in treatment options for non smoking lung cancer patients with identifiable andquot driverandquot mutations there have been relatively few advances in treatment of smoking induced lung cancers The research in this phase I STTR application exploits two important novel findings The first is data we recently obtained demonstrating that lung cancer patients treated with adjuvant cisplatin chemotherapy after surgery with high XPA xeroderma pigmentosum group A expression correlates with a decrease in overall survival This correlation is unique to XPA and not observed with other DNA repair genes consistent with XPA being the limiting factor in nucleotide excision repair NER These preliminary data serves as the rationale for targeting XPA for adjuvant combination therapy in this patient population The second advance driving this research is our recent development of novel XPA inhibitors XPA inhibitors We originally identified XPA inhibitors with modest activity IC andapos s of M an have recently developed derivatives with IC andapos s in the nM range In a single aim we will exploit our recently discovered structure activity relationships SAR to complete lead optimization to maximize bioavailability potency and specificity of XPA inhibitors We then will interrogate the i vivo effects including PK PD toxicity and efficacy Completion of these studies will provide essential information for IND enabling studies towards the development of a novel therapeutic treatment for smoking induced lung cancer PUBLIC HEALTH RELEVANCE The development of novel cancer therapeutics is directly relevant to human health

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government